Your search for baricitinib returned 13 results

Reduction in death seen at 28, 60 days for patients receiving invasive mechanical ventilation, extracorporeal membrane oxygenation

But placebo-controlled trial shows lower all-cause mortality at 28 days and 60 days in patients receiving baricitinib plus standard of care

Long-term sustained outcomes seen among adults with moderate-to-severe atopic dermatitis

Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.

Findings showed that the trial did not meet statistical significance on the primary endpoint.

Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.

Baricitinib, an oral Janus kinase 1 and 2 inhibitor, is superior to placebo in refractory rheumatoid arthritis, according to a study published in the New England Journal of Medicine.

Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay

Abrocitinib, 200 mg daily, and upadacitinib, 30 mg daily, slightly better than dupilumab, while upadacitinib, 15 mg daily is similar to dupilumab

JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19